Taysha Gene Therapies, Inc. TSHA
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a rare genetic drug developer. Its lead program, TSHA-102, is in Phase 2 for Rett syndrome (MECP2 loss-of-function). Its next catalyst on record is TSHA-102: REVEAL pivotal 6-month interim analysis topline data and FDA regulatory feedback toward BLA submission (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TSHA-102 — REVEAL pivotal 6-month interim analysis topline data and FDA regulatory feedback toward BLA submission (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TSHA-102 (REVEAL Phase 1/2 pivotal, Part B) | Rett syndrome, females aged 6 to <22 years (single-arm pivotal; 17 patients dosed, enrollment complete) | gene therapy | Phase 2 |
| TSHA-102 (REVEAL Phase 1/2 Part A, adolescent/adult and pediatric) | Rett syndrome (12 patients dosed, enrollment complete) | gene therapy | Phase 2 |
| TSHA-102 (ASPIRE) | Rett syndrome, ages 2 to <4 years (safety-focused; 4 patients dosed) | gene therapy | Phase 2 |
Recent results and decisions
- Aug 11, 2026completed enrollment Completed dosing in the overenrolled ASPIRE safety trial (4 patients aged 2 to <4 years).
Taysha completed dosing in the overenrolled ASPIRE trial, with a total of four patients with Rett syndrome, aged 2 to <4 years, dosed with TSHA-102.
Filing - Jun 22, 2026positive Longer-term Part A data: 100% of 12 patients gained/regained at least one developmental milestone by 12 months; 310 total functional gains (~26 per patient); no treatment-related SAEs or DLTs.
100% of patients gained/regained ≥one developmental milestone across the core functional domains of fine motor, gross motor and communication post-TSHA-102
Filing - Jun 22, 2026completed enrollment Completed dosing of 17 patients (overenrolled) in the single-arm REVEAL pivotal trial.
Completed dosing in the overenrolled REVEAL pivotal trial, with a total of 17 females in the developmental plateau population of Rett syndrome dosed with TSHA-102
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.